|
TORONTO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce the appointment of Dr. Robert A. Hauser, MD, MBA, as a scientific and clinical advisor to the Company. Dr. Hauser currently serves as Professor of Neurology and Director of the University of South Florida Parkinson’s Disease and Movement Disorders Center.
TORONTO, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that the Company has entered into an exclusive license agreement (the “Agreement”) with BioRAE, Inc., for the development and commercialization of a novel biocompatible and biodegradable gelatin methacryloyl microneedle (“GelMA-MN”) delivery technology developed at the University of California, Los Angeles (“UCLA”) for use with psychedelic pharmaceuticals, including, but not limited to Psilocybin, Ketamine, Ibogaine, LSD, MDMA, DMT, and Cannabinoids.
TORONTO, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that the Company has entered into an exclusive license agreement with the University of Arizona for the development and commercialization of ketamine in the treatment of Parkinson’s disease. Pharmather will seek U.S. Food and Drug Administration (“FDA”) approval of an investigational new drug (“IND”) application to conduct a Phase II clinical study this year.
Discovering and developing psychedelic pharmaceuticals to treat disorders of the brain and nervous system
TORONTO, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (d/b/a Pharmather) (“Pharmather” or the “Company”) (CSE: PHRM), a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that the Company's common shares have been approved for listing on the Canadian Securities Exchange (the "CSE") and the Company expects to begin trading on the CSE under the trading symbol "PHRM" as of market open on October 9, 2020. |
RSS Feed
10/29/2020